Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials

作者
Behnood Bikdeli,César Caraballo,John W. Welsh,Joseph S. Ross,Sanjay Kaul,Gregg W. Stone,Harlan M. Krumholz
出处
期刊:Clinical Trials [SAGE Publishing]
卷期号:17 (6): 723-728 被引量:2
标识
DOI:10.1177/1740774520949157
摘要

Background/aims Non-inferiority trials are increasing in cardiovascular medicine, with approval of many drugs and devices on the basis of such studies. Surrogate markers as primary endpoints have been also more frequently used for efficient assessment of cardiovascular interventions. However, there is uncertainty about their concordance with clinical outcomes. Non-inferiority design using a surrogate marker as a primary endpoint may pose particular challenges in clinical interpretation. We sought to explore the publication trends, methodology, and reporting features of non-inferiority cardiovascular trials that used a primary surrogate marker as the primary endpoint. Methods We searched six high-impact journals ( The New England Journal of Medicine, The Journal of the American Medical Association, The Lancet, The Journal of the American College of Cardiology, Circulation, and European Heart Journal) from 1 January 1990 to 31 December 2018 and identified non-inferiority cardiovascular trials that used a surrogate marker as the primary endpoint. We assessed the non-inferiority margin reported in the manuscript and other publicly available platforms (e.g. protocol, clinicaltrials.gov). We also determined whether the included non-inferiority trials with surrogate markers as primary endpoints were followed by clinical outcome trials. Results We screened 15,553 publications and identified 247 cardiovascular trials that used a non-inferiority design. Of these, 37 had a surrogate marker as a primary endpoint (18 drug trials, 13 device trials, 6 others). All of these non-inferiority trials with surrogate outcomes were published after 2000, mostly in cardiology journals (13 in The Journal of the American College of Cardiology, 9 in European Heart Journal, 8 in Circulation, 6 in The Lancet, 1 in The New England Journal of Medicine), and their publication rate increased over time (p < 0.001 for linear trend). The median number of patients in the primary analysis was 300 (interquartile range: 202–465). The study protocol or a methods paper was publicly available for only 13 (35.1%) trials, of which the non-inferiority margin was not reported in 4 trials. In 16 studies (43.2%), the manuscript did not acknowledge the limitations of using a surrogate endpoint or the need for a definitive clinical outcome trial. Thirty-four trials (91.9%) concluded that the tested intervention met non-inferiority criteria. However, only five (13.5%) were followed by clinical outcomes trials the results of which did not always confirm non-inferiority. Conclusion Non-inferiority trials that use a surrogate marker as the primary endpoint are being increasingly performed. However, these trials pose particular challenges with design, reporting, and interpretation, which are not systematically and consistently addressed or reported.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
dongxu发布了新的文献求助10
1秒前
1秒前
美满懿轩发布了新的文献求助10
1秒前
lei发布了新的文献求助10
3秒前
4秒前
chengzi发布了新的文献求助10
4秒前
something完成签到,获得积分10
4秒前
大模型的应助被贝利亚大王采纳,获得10
5秒前
5秒前
krislan完成签到,获得积分10
6秒前
LCX完成签到,获得积分20
6秒前
6秒前
7秒前
粗犷的天佑完成签到,获得积分20
7秒前
隐形曼青的应助被扑了空采纳,获得10
8秒前
1193727949发布了新的文献求助10
8秒前
Owen的应助被lnx采纳,获得10
9秒前
9秒前
9秒前
xiaofanwang完成签到,获得积分10
10秒前
10秒前
11秒前
凉笙完成签到 ,获得积分10
12秒前
搜集达人的应助被ywj采纳,获得10
12秒前
Aether完成签到,获得积分10
12秒前
hsn发布了新的文献求助20
13秒前
GXL发布了新的文献求助10
14秒前
yjh完成签到,获得积分10
14秒前
daladala发布了新的文献求助10
14秒前
15秒前
郑睿涛发布了新的文献求助10
15秒前
16秒前
江海共余生完成签到,获得积分20
18秒前
秋风的应助被杨某采纳,获得10
18秒前
秋风的应助被杨某采纳,获得10
18秒前
19秒前
ywj完成签到,获得积分10
19秒前
Tiko发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183423
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827410
捐赠科研通 7780522
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480357